SAMR fines pharma company for refusal to deal
China’s competition watchdog has fined a drugmaker nearly €13 million for refusing to supply an active pharmaceutical ingredient to downstream companies.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.